BCL6 and the Notch Pathway: A Signaling Axis Leading to a Novel Druggable Biotarget in Triple Negative Breast Cancer

Scientists investigated signaling cascades of B cell lymphoma 6 (BCL6) in the CSC compartment of triple negative breast cancers, and the mechanisms that govern its activity, mainly through Notch signaling.